Glaxo's New CEO Walmsley Pledges to Make Drugs the Priority
- Drugmaker reports 31 percent gain in first-quarter profit
- Walmsley says company will need to make ‘tough’ choices
This article is for subscribers only.
Emma Walmsley pledged to spur growth at GlaxoSmithKline Plc’s pharmaceutical unit less than a month after taking over as chief executive officer of the U.K.’s largest drugmaker.
“We are a science-based company,” Walmsley, who had been head of Glaxo’s consumer products division before her appointment in September, told reporters on Wednesday. “Our focus has got to be around strengthening the pipeline in all three businesses, but the priority is in the pharma business.”